Current therapeutic strategies for breast cancer are mostly aimed at controlling malignant disease. In most cases, these strategies extend a patient's lifespan, but are rarely successful in stopping the cancer. I believe that by gaining an understanding of the molecular mechanisms involved in development of premalignant lesions and progression to malignant cancer, we will be able to devise strategies to treat breast cancer early when there is a greater chance for cure. All invasive breast cancers originate from epithelial cells, which in the normal breast are arranged with a distinct polarized organization within ducts and lobules. Changes in cell polarity and organization are a key criterion used by pathologists in grading cancers, supporting the notion that regulation of cell polarity and tissue organization is a critical component of cancer progression. However, very little is known about the molecular mechanisms that regulate changes in cell polarity. It is my belief that mechanisms by which polarity pathways are altered in cancer represent an untapped area of cancer cell biology that offers tremendous potential for discovery of novel strategies for early diagnosis and treatment to effectively eradicate invasive breast cancer. During the past funding period we discovered that ErbB2 directly interacts with the Par6/aPKC polarity complex. This pathway was required for the ability of ErbB2 to disrupt cell polarity and inhibit cell death, but was dispensable to induce cell proliferation. These results have identified two major roles for polarity pathways in ErbB2 positive breast cancers - 1) to disrupt cell and tissue architecture;2) to inhibit cell death. The latter was an unexpected finding, which was not predicted by all the studies previously performed in Drosophila and Worms. In this proposal we propose to extend on these finding and develop a deeper understanding of the mechanisms by which ErbB2 interacts with the polarity protein and identify the pathways downstream of ErbB2-Par6 polarity complex that regulates cell death. In the process of these studies we will develop robust in vivo models that will not only allow us to determine the in vivo relevance of our finding but will also function as tools for preclinical studies. In addition to the above, we also propose extend the scope and investigate how alterations in polarity pathways promote invasive progression and metastasis. Thus, I believe that our proposal takes an innovative strategy and exploits an unexplored area of cancer biology with the goal of finding a new class of biomarkers and drug targets.
Pathologists routinely use changes in cell and tissue structure to understand cancer progression and make assessments for treatment options. However, the molecular pathways that regulate loss of normal cell and tissue structure is poorly studied. The goal of this proposal is to take a new perspective - understand breast cancer initiation and progression as a function of molecular pathways that regulate cell shape. We use three-dimensional organ cultures and mouse models to accomplish this goal. In addition, we collaborate with pathologists to determine the clinical relevance of our findings. This investigation is likely to identify a novel class of biomarkers and drug targets for premalignant and malignant carcinoma.
|Prudnikova, Tatiana Y; Rawat, Sonali J; Chernoff, Jonathan (2015) Molecular pathways: targeting the kinase effectors of RHO-family GTPases. Clin Cancer Res 21:24-9|
|Feigin, Michael E; Akshinthala, S Dipikaa; Araki, Kiyomi et al. (2014) Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res 74:3180-94|
|Radu, Maria; Semenova, Galina; Kosoff, Rachelle et al. (2014) PAK signalling during the development and progression of cancer. Nat Rev Cancer 14:13-25|
|Kelly, Mollie L; Astsaturov, Artyom; Rhodes, Jennifer et al. (2014) A Pak1/Erk signaling module acts through Gata6 to regulate cardiovascular development in zebrafish. Dev Cell 29:350-9|
|Xue, Bin; Krishnamurthy, Kannan; Allred, D Craig et al. (2013) Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat Cell Biol 15:189-200|
|Kosoff, Rachelle; Chow, Hoi Yee; Radu, Maria et al. (2013) Pak2 kinase restrains mast cell FcýýRI receptor signaling through modulation of Rho protein guanine nucleotide exchange factor (GEF) activity. J Biol Chem 288:974-83|
|Rawat, Sonali Jalan; Creasy, Caretha L; Peterson, Jeffrey R et al. (2013) The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylation and inactivation of peroxiredoxin-1 protein. J Biol Chem 288:8762-71|
|Arias-Romero, Luis E; Chernoff, Jonathan (2013) Targeting Cdc42 in cancer. Expert Opin Ther Targets 17:1263-73|
|Muthuswamy, Senthil K (2011) 3D culture reveals a signaling network. Breast Cancer Res 13:103|
|Muthuswamy, Senthil K (2011) Trastuzumab resistance: all roads lead to SRC. Nat Med 17:416-8|
Showing the most recent 10 out of 20 publications